MedTech Innovator Names Sana Health as 2018 Global Competition Winner at The MedTech Conference

MedTech Innovator, the premier nonprofit startup accelerator in the medical technology industry, today announced Sana Health as the winner of its 2018 global competition. The company was selected in a live audience vote on Sept. 25 at The MedTech Conference, powered by AdvaMed, in Philadelphia.

Why biotech startups need “smart capital”?

In many people's eyes, biotech companies are money blackholes. A typical startup spends its first 5 or even 10 years of life consuming huge sums of cash, without churning out any revenue, let alone profit. This doesn't sound like an attractive proposition to either entrepreneurs or investors. After all, everyone wants a bit more transparency and a little certainty along the journey. Is this possible?

How bereaved parents became ‘accidental world leaders’ in 3D printing

Naveed and Samiya Parvez watched their son, who had cerebral palsy, suffer distressing measuring methods to get the splints and braces he needed. Now, they’ve revolutionised the process

The biotech conundrum – is patient capital the solution?

Starting a biotech company is a monumental task. Entrepreneurs need to be prepared to commit for the long term, and spend tens or hundreds of millions of dollars before reaching the first customer. It is a dark and winding tunnel fraught with traps; at any point the doors can slam shut because of a tiny misstep, or from forces outside the founders’ control. The company can become worthless overnight if a key product fails to demonstrate sufficient efficacy in a clinical trial, or if the company can’t raise further capital to continue. 10 years of sweat and toil can go to waste in an instant.

New £50m venture capital fund will give a shot in the arm to UK life sciences

A brand new £50m venture capital fund launches today with a plan to invest in the UK's flourishing life sciences sector.

Scotland’s TCB inks CAR-T deal with Japan’s NIPRO

Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical activities.

Acerus Enters into a Licensing Agreement with Viramal to Commercialize the Elegant™ Franchise in Canada

Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has entered into a license, development and supply agreement with Viramal Limited (“Viramal”), a London-based specialty pharmaceutical company developing therapeutics that improve the quality of women’s health, granting Acerus the exclusive rights to commercialize the Elegant™ franchise in Canada.

bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy

– Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven expertise in all stages of CAR T and gene therapy product development to discover and develop …

Age of Discovery (PharmaTimes, November 2017)

Five years on from Pfizer selling Discovery Park, the site's current chief executive Toby Hunter tells PharmaTimes about the plans for its future.

NCL Innovation Leads Second Round of investment in Coomtech Ltd

NCL Innovation, the UK’s leading early stage technology investor, has joined a second financing round for Kent based start-up Coomtech Ltd. The investment was made via the NCL’s Discovery Park Technology Investment Fund (DPTIF).